Pharmaceutical

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.

Apr 23, 2024 - 00:00
Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Ovarian Cancer.
Read the original article

Tags:

Previous Article

Life goals and their changes drive success

Next Article

AlphaMedix by Orano Med for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NE...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Container Closure Integrity Testing (CCIT): How to get started with deterministic methods

Container Closure Integrity Testing (CCIT): How to get ...

Mar 29, 2023

STAT+: British Columbia to bar Americans from buying Ozempic over supply concerns

STAT+: British Columbia to bar Americans from buying Oz...

Mar 30, 2023

Datopotamab deruxtecan by Daiichi Sankyo for Metastatic...

Apr 23, 2024